A carregar...
DDIS-08. DEVELOPMENT OF BRAIN-PENETRANT EGFR INHIBITORS FOR GLIOBLASTOMA
The epidermal growth factor receptor (EGFR) is altered in nearly 60% of glioblastoma (GBM) tumors, however, EGFR tyrosine kinase inhibitors (TKIs) have failed to improve outcomes for GBM patients. This can be attributed to the inability of conventional EGFR TKIs (e.g., erlotinib, gefitinib, lapatini...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216525/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.287 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|